Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413992
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-23
Brief Title:
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-10
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-23
First Submit QC Date:
May 10 2024
Study First Post Date:
2024-05-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-10
Last Update Post Date:
2024-05-14
Last Update Post Date Type:
ACTUAL